These findings not only decipher the essential role of clathrin in the feedback EGFR/HER2 and Akt activation in response to ERK inhibition by MEK inhibitor, but also suggest HER2 expression as a potential marker to predict the therapeutic efficacy of patients with cancer to MEK inhibitors. This evidence concerns the gene MAP2K7 and cancer.